Miscellaneous therapies

  • Anthony A Bavry
  • Deepak L Bhatt


The prior two chapters discussed anti-platelet and anti-thrombin therapies for the treatment of ACS. Together they form the foundation for ACS management, especially during reperfusion therapy. However, other therapies, such as statins, beta-blockers and ACE inhibitors are also important. These therapies not only help to limit infarct size and reduce recurrent myocardial infarction, but also improve survival.


Percutaneous Coronary Intervention Acute Coronary Syndrome Acute Myocardial Infarction Statin Therapy Recurrent Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711–1718.CrossRefGoogle Scholar
  2. 2.
    Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295:2046–2056.CrossRefGoogle Scholar
  3. 3.
    Bavry AA, Mood GR, Kumbhani DJ, et al. Long-term benefit of statin therapy initiated during the hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs 2007; 7:135–141.CrossRefGoogle Scholar
  4. 4.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEJM 2004; 350:1495–1504.CrossRefGoogle Scholar
  5. 5.
    Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105:691–696.CrossRefGoogle Scholar
  6. 6.
    Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107:1750–1756.CrossRefGoogle Scholar
  7. 7.
    Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49:1272–1278.CrossRefGoogle Scholar
  8. 8.
    Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28:664–672.CrossRefGoogle Scholar
  9. 9.
    Shishehbor MH, Patel TN, Bhatt DL. Using statins to treat inflammation in acute coronary syndromes: are we there yet? Cleve Clin J Med 2006; 73:760–766.CrossRefGoogle Scholar
  10. 10.
    Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97:2202–2212.Google Scholar
  11. 11.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893–1906.CrossRefGoogle Scholar
  12. 12.
    Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730–1737.CrossRefGoogle Scholar
  13. 13.
    Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 32:634–640.CrossRefGoogle Scholar
  14. 14.
    Chen ZM, Pan HC, Chen YP, et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622–1632.CrossRefGoogle Scholar
  15. 15.
    Ellis K, Tcheng JE, Sapp S, et al. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 2003; 16:299–305.CrossRefGoogle Scholar
  16. 16.
    Chan AW, Quinn MJ, Bhatt DL, et al. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40:669–675.CrossRefGoogle Scholar
  17. 17.
    The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988; 319:385–392.CrossRefGoogle Scholar
  18. 18.
    ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669–685.CrossRefGoogle Scholar
  19. 19.
    Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. JAMA 2007; 297:1775–1783.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group, a part of Springer Science+Business Media 2008

Authors and Affiliations

  • Anthony A Bavry
    • 1
  • Deepak L Bhatt
    • 1
  1. 1.Department of Cardiovascular MedicineCleveland ClinicUSA

Personalised recommendations